Therapy Design
The usage of approved drugs for new applications, drug repurposing, based on the ‘omics-technologies is one of the strategies of the division Therapy Design within the ZPM. We use this approach in a strongly patient individualized way to achieve high specificity of tumor patient treatment. Therefore we analyze primary tumor samples of the patient with various molecular diagnostic procedures (tumor genome, epigenome, transcriptome) (Fig.1). With help of bioinformatical analysis, provided by the QBiC, we can identify candidate genes as tumor driver genes. From these examinations we compile lists of potential targets for pharmacological intervention and discuss them in interdisciplinary boards (oncologists, pharmacologists, molecular biologists, etc.). Out of these discussions personalised therapeutic concepts develop fitting one individual patient. Using already approved drugs these concepts can be realized immediately.
Main Objectives
- Establishment of ’omics-technologies and their analysis in matters of targeted therapy
- Identification of relevant tumor markers in interdisciplinary boards
- Virtual screening of target specific, approved drugs
- Establishment of a valid and fast process from the genetic analysis towards a tailored therapy concept
Members of the Division
- Prof. Dr. Stefan Laufer, Faculty of Science, Pharmaceutical and Medicinal Chemistry
- Prof. Dr. Frank M. Böckler, Faculty of Science, Pharmaceutical and Medicinal Chemistry, molecular design and pharmaceutical biophysics
- Prof. Dr. Peter Heutink, German Center for Neurodegenerative Diseases (DZNE)
- Prof. Dr. med. Ulrich M. Lauer, Internal Medicine I, Gastroenterology, Hepatology and Infectious Diseases
- Prof. Dr. Martin E. Maier, Faculty of Science, Inst. of Organic Chemistry
- Dr. med. Hoa Huu Phuc Nguyen, Inst. of Medical Genetics and Applied Genomics
- Prof. Dr. Hans-Georg Rammensee, Interfaculty Inst. for Cell Biology (IFIZ), Dept. of Immunology
- Prof. Dr. Matthias Schwab, Dr Margarete Fischer-Bosch Inst. of Clinical Pharmacology
- Prof. Dr. Wolfgang Wohlleben, Interfaculty Inst. of Microbiology and Infection Medicine Tübingen (IMIT), Dept. of Microbiology/Biotechnology